Zenas BioPharma, Inc. (ZBIO) Investor Relations Documents

Zenas BioPharma, Inc. (ZBIO) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-08-12. Read in-app with summaries. First-party data.

Corporate Presentation: Zenas BioPharma's August 2026 presentation details its I&I pipeline, highlighting Obexelimab for IgG4-RD with positive INDIGO trial data and upcoming BLA decision, and

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-18Press releasePDF Version
2026-08-18Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-08-13Press releasePDF Version
2026-08-13Press releaseZenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12PresentationCorporate Presentation
2026-07-17Press releasePDF Version
2026-07-17Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-17Press releasePDF Version
2026-06-17Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-11Press releaseZenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-02Press releasePDF Version
2026-06-02Press releaseZenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related D
2026-05-28Press releasePDF Version
2026-05-28Press releaseZenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
2026-05-19Press releasePDF Version
2026-05-19Press releaseZenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imm
2026-05-18Press releasePDF Version
2026-05-18Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-13Press releasePDF Version
2026-05-13Press releasePDF Version
2026-05-13Press releaseZenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13Press releaseZenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Ora
2026-04-17Press releasePDF Version
2026-04-17Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-27Press releasePDF Version
2026-03-27Press releaseZenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common S
2026-03-26Press releasePDF Version
2026-03-26Press releaseZenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
2026-03-16Press releasePDF Version
2026-03-16Press releasePDF Version
2026-03-16Press releaseZenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2026-03-16Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-20Press releasePDF Version
2026-02-20Press releaseZenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-09Press releasePDF Version
2026-02-09Press releaseZenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in R
2026-02-04Press releaseZenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2026-01-16Press releasePDF Version
2026-01-16Press releaseZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-01-05PresentationView Presentation

ZBIO overview · ZBIO earnings · ZBIO financials · ZBIO KPIs · ZBIO documents · ZBIO ownership · ZBIO peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.